New Pediatric Dosing for Aptivus, Patients 2-18 Years, New Oral Solution and Info on Coadministration With Midazolam

Print this page • Back to Web version of article

Press Release

June 23, 2008

On June 23, 2008, FDA approved a new Aptivus (tipranavir) oral solution (100 mg/mL). The product label has been updated to include dosing recommendations for pediatric patients 2-18 years of age.

In addition, information regarding oral and parenterally administered midazolam was updated in the Contraindication and Drug Interactions section.

Please see the attached pdf file for specific pediatric labeling information and for updated information about midazolam.

This article was provided by U.S. Food and Drug Administration. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/treat/art47781.html

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.